checkAd

     229  0 Kommentare Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis - Seite 3

    ENLIVEX CONTACT                                                                            
    Shachar Shlosberger, CFO                                                                    
    Enlivex Therapeutics, Ltd.                                                                      
    shachar@enlivexpharm.com

    INVESTOR RELATIONS CONTACT
    Dave Gentry, CEO
    RedChip Companies Inc.
    1-407-644-4256

    ENLV@redchip.com 



    1 Source: The Arthritis Foundation; Disease modification in osteoarthritis; pathways to drug approval, Katz et. Al., Osteoarthritis and Cartilage Open (2) (2020)

    Lesen Sie auch



    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis - Seite 3 Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first two patients have been dosed in the …